Flexibility of alternative trial designs crucial for cell and gene therapy research
On Clinical Trials Day, we take a look at how sponsors are exploring alternative designs to study cell and gene therapies.
On Clinical Trials Day, we take a look at how sponsors are exploring alternative designs to study cell and gene therapies.
Sipavibart demonstrated to offer a statistically significant decline in the symptomatic Covid-19 occurrence.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Allucent receives grant for decentralised Covid-19 vaccine trial
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment